2019
Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death
Valentino PL, Emre S, Geliang G, Li L, Deng Y, Mulligan D, Rodriguez-Davalos M. Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death. American Journal Of Transplantation 2019, 19: 3114-3123. PMID: 31152483, DOI: 10.1111/ajt.15481.Peer-Reviewed Original ResearchConceptsAdult recipientsTransplantation Network/United NetworkNumber of allograftsOrgan Sharing dataSplit-liver transplantationCareful patient selectionDeceased donor liversNumber of LTLT graftSLT recipientsUnderwent LTWLT recipientsPediatric candidatesPatient selectionDonor liversOrgan utilizationUnited NetworkOrgan shortageOrgan procurementSmall childrenRecipientsTransplantation
2016
De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemia
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2010
Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus
Chakkera HA, Bodner JK, Heilman RL, Mulligan DC, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Ray RM, Beck GL, Reddy KS. Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus. Transplantation Proceedings 2010, 42: 2650-2652. PMID: 20832562, PMCID: PMC3060052, DOI: 10.1016/j.transproceed.2010.04.065.Peer-Reviewed Original ResearchMeSH KeywordsAdultC-PeptideCreatinineDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NephropathiesDiabetic RetinopathyFemaleFollow-Up StudiesGlycated HemoglobinGraft RejectionHumansKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPancreas TransplantationRetrospective StudiesSurvival AnalysisTissue DonorsConceptsEnd-stage renal diseaseType of diabetesC-peptideSimultaneous pancreasKidney transplantationPatient survivalGlutamic acid decarboxylase antibodiesType 2 diabetes mellitusDetectable C-peptideMean creatinine clearanceRenal Disease equationModification of DietBody mass indexC-peptide measurementsRegression survival analysisGlycosylate hemoglobinDiabetic ketoacidosisESRD patientsPancreas transplantationT2DM patientsCreatinine clearanceDecarboxylase antibodiesOral hypoglycemicsRenal replacementDiabetes mellitusAlemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Reddy K, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin. Transplantation Proceedings 2010, 42: 2006-2008. PMID: 20692393, DOI: 10.1016/j.transproceed.2010.05.090.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumCreatinineDrug Therapy, CombinationGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMycophenolic AcidPancreas TransplantationPatient SelectionRetrospective StudiesConceptsRapid steroid taperAcute rejection episodesR-ATG groupR-ATGSimultaneous kidneySteroid taperBK nephropathyRejection episodesPancreas transplantationAlemtuzumab groupClinical acute rejection episodesRabbit antithymocyte globulin inductionAntithymocyte globulin inductionR-ATG inductionMean serum creatinineHistoric control groupPostoperative day 4Alemtuzumab inductionAntithymocyte globulinGlobulin inductionMaintenance immunosuppressionTransplant characteristicsGraft survivalCMV infectionCytomegalovirus infectionImpact of Subclinical Inflammation on the Development of Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients
Heilman RL, Devarapalli Y, Chakkera HA, Mekeel KL, Moss AA, Mulligan DC, Mazur MJ, Hamawi K, Williams JW, Reddy KS. Impact of Subclinical Inflammation on the Development of Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients. American Journal Of Transplantation 2010, 10: 563-570. PMID: 20121731, DOI: 10.1111/j.1600-6143.2009.02966.x.Peer-Reviewed Original ResearchConceptsIF/TA scoreRapid steroid withdrawalSubclinical acute rejectionClinical acute rejectionSubclinical inflammationGroup 2Group 1Group 3Acute rejectionTubular atrophyInterstitial fibrosisGroup 4IF/TAProtocol biopsy findingsKidney transplant recipientsTA scoresProtocol biopsiesSteroid withdrawalTransplant recipientsBiopsy findingsInterstitial inflammationMore patientsMonths 1High riskPatients
2009
Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course
Gallegos‐Orozco J, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation 2009, 15: 1872-1881. PMID: 19938138, DOI: 10.1002/lt.21954.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultBiopsyDisease ProgressionFemaleGraft RejectionHepatitis CHumansKaplan-Meier EstimateLiver CirrhosisLiver FailureLiver TransplantationLiving DonorsMaleMiddle AgedProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsEnd-stage liver diseaseHCV-positive recipientsLiver transplantHepatocellular carcinomaHCV recurrenceAcute rejectionPatient survivalBiopsy-proven acute rejectionMedian age 53 yearsHistory of HCCAggressive HCV recurrenceEarly acute rejectionProtocol liver biopsiesSignificant HCV recurrenceAdult liver transplantsAdvanced donor ageAge 53 yearsAge 39 yearsDay of transplantationLong-term survivalElectronic medical recordsAvoidance of rejectionEvaluable populationRapid fibrosersHepatitis CUse of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Clinical Transplants 2009, 407-14. PMID: 20524306.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAgedAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmBoronic AcidsBortezomibCreatinineFemaleGraft RejectionHLA AntigensHumansImmunoglobulins, IntravenousImmunosuppressive AgentsIsoantibodiesKidney TransplantationMaleMiddle AgedProtease InhibitorsPyrazinesRituximabTreatment Outcome
2007
Laparoscopic incisional hernia repair after liver transplantation
Mekeel K, Mulligan D, Reddy KS, Moss A, Harold K. Laparoscopic incisional hernia repair after liver transplantation. Liver Transplantation 2007, 13: 1576-1581. PMID: 17969189, DOI: 10.1002/lt.21290.Peer-Reviewed Original ResearchConceptsLaparoscopic incisional hernia repairIncisional hernia repairLAP groupLiver transplantationHernia repairOP groupMore patientsLaparoscopic ventral hernia repairTime of transplantationLength of stayVentral hernia repairNontransplant patientsPrimary immunosuppressionWound complicationsRecurrent ascitesLaparoscopic approachMesh removalOpen repairRetrospective reviewDecreased incidenceMesh infectionIncisional herniaLower riskPatientsTransplantation
2006
Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk
2005
Immunosuppression in liver transplantation
Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transplantation 2005, 11: 1307-1314. PMID: 16237688, DOI: 10.1002/lt.20614.Peer-Reviewed Original Research
2004
Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients
Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas DD. Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. Digestive Diseases And Sciences 2004, 49: 38-41. PMID: 14992432, DOI: 10.1023/b:ddas.0000011599.78222.9e.Peer-Reviewed Original ResearchConceptsDeceased donor transplantationHepatitis C virusLiver transplantationLDLT groupDonor liver transplant recipientsHepatitis C virus recurrenceEnd-stage liver diseaseHCV RNA titersLiver transplant populationLiver transplant recipientsIncidence of rejectionHistological recurrenceChronic hepatitisTransplant recipientsVirus recurrenceDonor transplantationTransplant populationHCV PCRLiver biopsyLiver diseaseAggressive recurrenceSingle pathologistC virusRNA titersInstitutional protocol
1997
Influence of steroid withdrawal on proteinuria in renal allograft recipients
Ghandour FZ, Knauss TC, Mulligan DC, Schulak JA, Hricik DE. Influence of steroid withdrawal on proteinuria in renal allograft recipients. Clinical Transplantation 1997, 11: 395-398. PMID: 9361929, DOI: 10.1111/j.1399-0012.1997.tb00840.x.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnalysis of VarianceAnti-Inflammatory AgentsAzathioprineChi-Square DistributionChronic DiseaseCreatinineCyclosporineFemaleFollow-Up StudiesGlucocorticoidsGraft RejectionHumansImmunosuppressive AgentsKidney TransplantationLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrednisoneProteinuriaRecurrenceTransplantation, HomologousConceptsSteroid withdrawalUrinary protein excretionAllograft rejectionProtein excretionPrimary renal transplant recipientsAcute allograft rejectionRenal allograft recipientsRenal transplant recipientsChronic allograft rejectionSpot urine specimensAcute rejectionAllograft recipientsSteroid therapyTransplant recipientsClinical variablesUrine creatinineUrine specimensPatientsProteinuriaWithdrawalExcretionRecipientsRejectionCreatinineTransplantationReduction of early rejection in adult liver transplantation with ATG induction therapy
Schulak J, May E, Post A, Fasola C, Mulligan D, Sterling R. Reduction of early rejection in adult liver transplantation with ATG induction therapy. Transplantation Proceedings 1997, 29: 555-556. PMID: 9123126, DOI: 10.1016/s0041-1345(96)00264-3.Peer-Reviewed Original Research
1995
Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor
Mulligan D, Gentry L, Dombrausky L, Klintmalm G, Nikaein A. Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor. Clinical Transplantation 1995, 9: 438-441. PMID: 8645885, DOI: 10.1111/j.1399-0012.1995.tb00363.x.Peer-Reviewed Original ResearchConceptsOKT3 MoAbPatient seraPanel reactive antibody (PRA) assayPositive reactivityAnti-HLA antibodiesHLA-specific antibodiesOKT3 monoclonal antibodyFalse-positive reactivityMismanagement of patientsAllograft recipientsHumoral rejectionTransplant recipientsAntibody assaysRabbit antimouse immunoglobulinAntibody developmentMonoclonal antibodiesMoAbSerumAntibodiesAntimouse immunoglobulinRecipientsComplicating factorsOKT3PatientsImmunoglobulin
1993
Baylor update: outcome analysis in liver transplantation.
Levy M, Goldstein R, Husberg B, Gonwa T, Backman L, Abouljoud M, Mulligan D, Klintmalm G. Baylor update: outcome analysis in liver transplantation. Clinical Transplants 1993, 161-73. PMID: 7918148.Peer-Reviewed Original ResearchConceptsLiver transplantationLong-term renal functionHepatitis B antigenemiaLate graft lossKaplan-Meier curvesGraft lossYear posttransplantLiver transplantElderly patientsRenal functionClinical correlatesOutcome analysisWhole bloodDisappointing resultsPlasma assaysPatientsTransplantationCurrent protocolsLife dataAntigenemiaPosttransplantDiabeticsCholangiocarcinomaTransplantBlood